December 11, 2024 07:00 AM Eastern Standard Time NEW HAVEN, Conn.–(BUSINESS WIRE)–Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions, announced today the closing of a $75 million…
San Antonio, TX – According to filings with the U.S. Securities and Exchange Commission, VeraDermics is raising $22,238,328.00 in new funding. Sources indicate as part of senior management President, Timothy Durso played a key role…
San Antonio, TX – According to filings with the U.S. Securities and Exchange Commission, VeraDermics is raising $1,500,000.00 in new funding. Sources indicate as part of senior management President, Timothy Durso played a key role…